Johnson & Johnson Vision has received US Food and Drug Administration (FDA) clearance, Health Canada approval and completed CE Mark activities for its latest contact lens (CL) innovations, Acuvue Oasys Max 1-Day and Acuvue Oasys Max 1-Day 1-Day Multifocal. 

The new lenses are developed to provide all-day comfort and visual clarity, with modern lifestyles taking their toll on eye comfort. A recent survey found the majority (71%) of eyecare professionals are seeing patients who are experiencing eye discomfort related to increased screen-time, with young CL wearers spending an average of nine hours per day in front of a screen, causing them to blink less and experience more dryness and eye fatigue. 

Available in spherical and multifocal, the new Acuvue Oasys Max 1-Day contact lenses are due for launch in the US, Canada and many European countries later in the year.